Group 1 - Bawang Chaji plans to open 1,000 new stores in mainland China, 50 in Hong Kong, and 110 overseas by 2025 [2] - Chinese companies are expanding into Brazil, marking a significant development in the country's internet sector [3] - Thailand has emerged as a leading market for TikTok e-commerce due to its stable and balanced market conditions [4] Group 2 - Yiwu business owners are facing challenges as U.S. merchants struggle to repay debts amid trade tensions [5] - 52TOYS is preparing for a Hong Kong IPO with a reported loss of 122 million, while 23% of its revenue comes from overseas [6] - Square and Harmony Technology have secured nearly 100 million in Series B funding to expand their smart production capabilities in the optical medical sector [7] Group 3 - OpenAI is collaborating with former Apple executives to produce 100 million hardware units for AI applications [8] - U.S. importers are rapidly building bonded warehouses to stockpile Chinese goods in response to trade policy uncertainties [9] - Miniso reported that its overseas stores reached 3,213 by March 31, 2025, with a 30% year-on-year increase in overseas revenue [9] Group 4 - Roborock aims for global scale deployment of its autonomous driving technology, having recently entered Dubai and Abu Dhabi [9] - Cainiao is accelerating the commercialization of its autonomous vehicles, with plans to deploy over 200,000 units in the next three to five years [10] - OpenAI has launched its first international project in the UAE, with plans for significant investment in AI infrastructure [11] Group 5 - EV Electra plans to invest $1 billion in restructuring high-end electric vehicle company Hozon, with commitments for significant overseas procurement [11]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球骨科大会 | 奖项评选 2025年3月22日， 昊海生科 发布了2024年年报。 # 财报数据 # 关于昊海生科 报名：首届全球眼科大会 | 名额有限 报名：首届全球心血管大会 | 奖项申报 2024年营业收入 26.98亿 元，同比增长1.64%； 归母净利润4.20亿元，同比增长1.04%；扣非归母净 利润3.79亿元，同比下滑1.12%。 2024Q4营业收入 6.23亿 元，同比下滑7.35%，环比增长9.74%； 归母净利润0.80亿元，同比下降 10.93%；扣非归母净利润0.58亿元，同比下滑26.83%。 分产品：2024年医疗美容与创面护理产品收入11.95亿元，同比增长13.08%，其中玻尿酸产品收入 7.42亿元，同比增长23.23%；眼科产品收入8.58亿元，同比下降7.60%；骨科产品收入4.57亿元，同 比下降4.11%；防粘连及止血产品1.46亿元，同比下降0.58%；其他产品收入0.38亿元，同比增长 1.56%。 2024 年公司整体毛利率为 69.89%，与上年度的 70.46%相比略有下降，其中，医美玻尿酸产品收入 ...